Prelis
Prelis - General Information
A selective adrenergic beta-1-blocking agent with no stimulatory action. It&
Pharmacology of Prelis
Prelis, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).
Prelis for patients
Metoprolol succinate is used to treat high blood pressure alone or in combination with other medications. This medication can also be used to treat a heart condition called angina. This particular formulation is an extended release product, meaning it can be taken once a day. This medication should be taken as directed, with a meal or right after a meal. The tablets should not be broken or crushed. Do not take a double dose if a dose is missed. This medication should not be stopped abruptly; it should be discontinued slowly over time. If you are taking this medication for high blood pressure, make sure to have your blood pressure checked regularly. If you ever have trouble breathing, call your physician immediately. The most common adverse effects are dizziness and tiredness. It is important to inform all your healthcare providers that you are taking this medication, especially before any surgeries or procedures.
Prelis Interactions
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with extended release metoprolol succinate plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Prelis Contraindications
Hypertension and Angina: Extended release metoprolol succinate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure
Additional information about Prelis
Prelis Indication: For the treatment of hypertension and angina pectoris.
Mechanism Of Action: Like betaxolol and atenolol, metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.
Drug Interactions: Acetohexamide The beta-blocker decreases the symptoms of hypoglycemia
Chlorpropamide The beta-blocker decreases the symptoms of hypoglycemia
Cimetidine Cimetidine increases the effect of the beta-blocker
Clonidine Increased hypertension when clonidine stopped
Disopyramide The beta-blocker increases toxicity of disopyramide
Gliclazide The beta-blocker decreases the symptoms of hypoglycemia
Glipizide The beta-blocker decreases the symptoms of hypoglycemia
Glisoxepide The beta-blocker decreases the symptoms of hypoglycemia
Glibenclamide The beta-blocker decreases the symptoms of hypoglycemia
Glycodiazine The beta-blocker decreases the symptoms of hypoglycemia
Insulin The beta-blocker decreases the symptoms of hypoglycemia
Lidocaine The beta-blocker increases the effect and toxicity of lidocaine
Propafenone Propafenone increases the effect of beta-blocker
Repaglinide The beta-blocker decreases the symptoms of hypoglycemia
Rifampin Rifampin decreases the effect of the metabolized beta-blocker
Telithromycin Telithromycin may possibly increase metoprolol effect
Tolazamide The beta-blocker decreases the symptoms of hypoglycemia
Tolbutamide The beta-blocker decreases the symptoms of hypoglycemia
Amobarbital The barbiturate decreases the effect of metabolized beta-blocker
Aprobarbital The barbiturate decreases the effect of metabolized beta-blocker
Butalbital The barbiturate decreases the effect of metabolized beta-blocker
Butabarbital The barbiturate decreases the effect of metabolized beta-blocker
Butethal The barbiturate decreases the effect of metabolized beta-blocker
Dihydroquinidine barbiturate The barbiturate decreases the effect of metabolized beta-blocker
Heptabarbital The barbiturate decreases the effect of metabolized beta-blocker
Hexobarbital The barbiturate decreases the effect of metabolized beta-blocker
Methohexital The barbiturate decreases the effect of metabolized beta-blocker
Methylphenobarbital The barbiturate decreases the effect of metabolized beta-blocker
Pentobarbital The barbiturate decreases the effect of metabolized beta-blocker
Phenobarbital The barbiturate decreases the effect of metabolized beta-blocker
Primidone The barbiturate decreases the effect of metabolized beta-blocker
Quinidine barbiturate The barbiturate decreases the effect of metabolized beta-blocker
Secobarbital The barbiturate decreases the effect of metabolized beta-blocker
Talbutal The barbiturate decreases the effect of metabolized beta-blocker
Citalopram The SSRI increases the effect of the beta-blocker
Escitalopram The SSRI increases the effect of the beta-blocker
Fluoxetine The SSRI increases the effect of the beta-blocker
Sertraline The SSRI increases the effect of the beta-blocker
Paroxetine The SSRI increases the effect of the beta-blocker
Dihydroergotamine Ischemia with risk of gangrene
Dihydroergotoxine Ischemia with risk of gangrene
Ergonovine Ischemia with risk of gangrene
Ergotamine Ischemia with risk of gangrene
Methysergide Ischemia with risk of gangrene
Verapamil Increased effect of both drugs
Hydralazine Increased effect of both drugs
Diltiazem Increased risk of bradycardia
Epinephrine Hypertension, then bradycardia
Fenoterol Antagonism
Formoterol Antagonism
Isoproterenol Antagonism
Orciprenaline Antagonism
Pirbuterol Antagonism
Prazosin Risk of hypotension at the beginning of therapy
Procaterol Antagonism
Salbutamol Antagonism
Salmeterol Antagonism
Terbutaline Antagonism
Ibuprofen Risk of inhibition of renal prostaglandins
Indomethacin Risk of inhibition of renal prostaglandins
Piroxicam Risk of inhibition of renal prostaglandins
Food Interactions: Avoid alcohol.
Take with food.
Avoid natural licorice.
Generic Name: Metoprolol
Synonyms: Metoprolol Tartrate; Metoprolol succinate
Drug Category: Sympatholytics; Antihypertensive Agents; Antiarrhythmic Agents; Adrenergic Agents
Drug Type: Small Molecule; Approved; Investigational
Other Brand Names containing Metoprolol: Beloc; Betaloc; Lopressor HCT; Lopresor; Lopresoretic; Lopressor; Metroprolol; Prelis; Selo-Zok; Seloken; Selopral; Toprol; Toprol-XL;
Absorption: Rapid and complete, 50%
Toxicity (Overdose): LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice)
Protein Binding: 12%
Biotransformation: Primarily hepatic
Half Life: 3-7 hours
Dosage Forms of Prelis: Solution Intravenous
Liquid Intravenous
Tablet, extended release Oral
Tablet Oral
Chemical IUPAC Name: 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
Chemical Formula: C15H25NO3
Metoprolol on Wikipedia: https://en.wikipedia.org/wiki/Metoprolol
Organisms Affected: Humans and other mammals